Enzon Pharmaceuticals (OTCMKTS:ENZN) Announces Quarterly Earnings Results

Enzon Pharmaceuticals (OTCMKTS:ENZN) released its quarterly earnings results on Friday. The biotechnology company reported ($0.01) earnings per share for the quarter, Zacks reports.

Enzon Pharmaceuticals Price Performance

ENZN opened at $0.09 on Friday. Enzon Pharmaceuticals has a fifty-two week low of $0.07 and a fifty-two week high of $0.24. The company’s 50 day moving average price is $0.10 and its two-hundred day moving average price is $0.12. The firm has a market capitalization of $6.99 million, a price-to-earnings ratio of 9.43 and a beta of 0.25.

About Enzon Pharmaceuticals

Enzon Pharmaceuticals, Inc, together with its subsidiaries, does not have significant operations. Previously, the company marketed its patented drug product, PegIntron. It also had a marketing agreement with Micromet AG relating to the Vicineum drug; and a licensing agreement regarding SC Oncaspar and certain other drugs.